Shots:
- Roche has reported P-III (FENhance 1) trial results in RMS pts, randomized to either fenebrutinib (PO, BID) with PBO-matched to teriflunomide or teriflunomide (PO, QD) with PBO matched to fenebrutinib
- Trial met its 1EP, reducing ARR by 51% over ≥96wks., consistent with the P-III (FENhance 2) study showing 59% reduction, while 2EPs showed significant reductions in brain lesions, with favorable trends observed across progression endpoints
- Detailed FENhance 1 & 2 data will be presented at the AAN 2026, & submitted along with FENtrepid study results in primary progressive multiple sclerosis to the regulatory authorities
Ref: Roche | Image: Roche | Press Release
Related News: The US FDA Accepts Roche’s Giredestrant NDA for ESR1-Mutated, ER-Positive Advanced Breast Cancer
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
